Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Edward Marut

Reproductive Endocrinology Glenview, IL Medical Doctor

NPI 1134104193 CMS profile 1285426

3703 W Lake Ave, Ste 310-Attn Fci, Glenview, IL 60026

Open in the dashboard

General payments

$3,932

58 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Edward Marut of Glenview, IL is reported in the CMS Open Payments database as having received $3,932 across 58 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $3,116 8
2020 General $263 13
2019 General $553 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Marut
  • Reproductive Endocrinology median
  • Middle half of Reproductive Endocrinology
  • National median

In program year 2025, general payments to Edward Marut were reported at $0. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.

Show as a table
Year Edward Marut Reproductive Endocrinology median Middle half National median
2019 $553 $196 $77–$425 $163
2020 $263 $81 $35–$182 $114
2021 $3,116 $102 $43–$247 $132
2022 $0 $139 $62–$303 $149
2023 $0 $141 $65–$285 $160
2024 $0 $144 $65–$302 $164
2025 $0 $141 $66–$285 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. EMD Serono, Inc. $3,098 9 payments
  2. Ferring Pharmaceuticals Inc. $334 19 payments
  3. AbbVie, Inc. $207 5 payments
  4. Merck Sharp & Dohme Corporation $191 19 payments
  5. Vertical Pharmaceuticals, LLC $63 3 payments
  6. Duchesnay USA Incorporated $15 1 payment
  7. Avion Pharmaceuticals $12 1 payment
  8. IBSA Pharma Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Consulting Fee $2,925 2 payments
  2. Food and Beverage $948 51 payments
  3. Education $60 5 payments
Products named General payments · program years 2019–2021
  1. FOLLISTIM AQ $191 19 payments
  2. ENDOMETRIN $144 7 payments
  3. Orilissa Endocrinology $139 2 payments
  4. MENOPUR $136 10 payments
  5. GANIRELIX $120 15 payments
  6. Gonal-f $51 4 payments
  7. FOLLISTIM AQ PEN DEVICE $44 4 payments
  8. ORILISSA Womens Health $43 2 payments
  9. INVOCELL $33 1 payment
  10. GANIRELIX ACETATE $32 2 payments
  11. Other $127 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Obstetrics & Gynecology: 65

Drug cost

$1,151

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

100%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol (Once Weekly) Estradiol Brand 11 $1,151

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Records

58 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Reproductive Endocrinology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record